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Apoptosis signal-regulating kinase 1 (ASK1) is a mitogen-activated protein kinase (MAPK) kinase kinase that activates the
downstream MAPKs, c-Jun N-terminal kinase (JNK) and p38. ASK1 is activated by various types of stress, such as oxidative
stress, endoplasmic reticulum stress, and infection, and regulates various cellular functions. Recently, it has been reported that
ASK1 is associated with various diseases induced by oxidative stress. In this review, we introduce recent ﬁndings of the regulatory
mechanisms of ASK1 and the oxidative stress-induced diseases mediated by the ASK1 signaling pathway.
1.Introduction
Cells are exposed to various types of external and internal
stresses and need to respond to these stresses to maintain
homeostasis. The mitogen-activated protein kinase (MAPK)
pathway is one of the intracellular signaling systems that
regulate various cellular functions, such as proliferation,
diﬀerentiation, and apoptosis. Each MAPK pathway consists
of three classes of protein kinases: MAPK kinase kinase
(MAP3K), MAPK kinase (MAP2K), and MAPK. MAP3K
phosphorylates and thereby activates MAP2K, and activated
MAP2K, in turn, phosphorylates and activates MAPK.
Among MAPKs, c-Jun N-terminal kinase (JNK) and p38
MAPK respond to various types of stress, including reactive
oxygen species (ROS), osmotic pressure, tumor necrosis
factor-α (TNF-α), and endoplasmic reticulum (ER) stress,
and regulate apoptosis, inﬂammation, and morphogenesis
through the phosphorylation of various target molecules [1].
MAP3Ks control the activation status of MAPKs, and thus,
MAP3Ks are important for the regulation of various cellular
responses.
Apoptosis signal-regulating kinase 1 (ASK1) is a member
of the MAP3K family, which activates the MAPK kinase
4 (MKK4)/MKK7-JNK and MKK3/6-p38 pathways [1, 2].
ASK1 is preferentially activated in response to various types
of stress, such as ROS, TNF-α, lipopolysaccharide (LPS),
and ER stress, and has pivotal roles in a wide variety of
cellular responses, including apoptosis, diﬀerentiation, and
inﬂammation [2–7]. Therefore, the excessive activation and
dysregulation of ASK1 are closely linked to various diseases.
Here, we focus on the molecular mechanisms of ASK1
activation and the involvement of ASK1 in oxidative stress-
induced diseases.
2. Mechanisms of ROS-Induced
ASK1Activation
ASK1 forms a high molecular mass complex termed the
ASK1 signalosome [8]. Within the signalosome, ASK1 is
homooligomerizedthroughitsC-terminalcoiled-coil(CCC)
domain, a process that is critical for ASK1 activation.
Thioredoxin (Trx), a redox-responsive protein, is included in
the ASK1 signalosome, and the reduced form of Trx binds
to the N-terminal region of ASK1 and inhibits its kinase
activity. However, the oxidized form of Trx dissociates from
ASK1 in response to ROS, and ASK1 is then activated by the
autophosphorylation of Thr845 in its kinase domain [3, 9].
Upon ROS-dependent dissociation of Trx from ASK1, ASK1












































region of ASK1 in response to ROS. Subsequently, TRAF2 and TRAF6 are recruited, thereby fully activating ASK1. The ROS-induced
activation of ASK1 results in its ubiquitination and proteasome-dependent degradation. USP9X negatively regulates ASK1 degradation by
deubiquitination, leading to the sustained activation of ASK1. CCC: C-terminal coiled-coil domain; NCC: N-terminal coiled-coil domain.
coiled-coil (NCC) domain, leading to the full activation of
ASK1.
The ROS-stimulated ASK1 signalosome forms a much
higher molecular mass complex than when not stimulated
and contains various regulatory factors of ASK1, includ-
ing TNF-α receptor-associated factor 2 (TRAF2), TRAF6,
protein phosphatase 5 (PP5), and USP9X [8, 10, 11]. In
response to ROS, the adaptor proteins TRAF2 and TRAF6
arerecruitedtotheASK1signalosomeandpositivelyregulate
ASK1 activity by promoting the homophilic interaction of
its NCC domain [12]. TRAF2 and TRAF6 promote ASK1-
dependent cell death and inﬂammatory cytokine production
downstream of the TNF-α receptor and Toll-like receptor 4
(TLR4; a receptor for LPS), respectively. PP5 dephosphory-
lates the activating phosphorylation site of ASK1 in a ROS-
dependent manner and negatively regulates ASK1 activity
[10].
The USP9X deubiquitination enzyme also binds to
ASK1 in response to oxidative stress. The oxidative stress-
induced activation of ASK1 results in the ubiquitination and
proteasome-dependent degradation of ASK1. Thus, USP9X
positively regulates ASK1 activity and ASK1-dependent cell
death through the deubiquitination and stabilization of
ASK1 [11]. Therefore, ASK1 activity is regulated by both
phosphorylation and ubiquitination in response to oxidative
stress (Figure 1).
3. Cancer and ASK1
Recently, it has been reported that ASK1 has an important
role in skin tumorigenesis [22]. The ROS-induced activation
of the ASK1-p38 pathway leads to the production of inﬂam-
matory cytokines, such as TNF-α, IL-6, and IL-1β,i nd e n -
dritic cells and macrophages [6], and the ASK1-dependent
production of inﬂammatory cytokines was found to be
critical for chemically induced skin tumorigenesis during the
promotion stage. In this case, ASK1 acts as a promoter of
skintumorigenesis.WhenASK1actswithASK2,afunctional
binding partner of ASK1, during the initiation stage of skin
tumorigenesis, ASK1 contributes to the induction of ROS-
dependent apoptosis in epidermal keratinocytes. Because the
ASK1-ASK2 complex functions as a tumor suppressor, the
expression level of ASK2 appears to regulate the roles of
ASK1 as a tumor promoter and suppressor. It has been
observed that the expression of ASK2 was strongly reduced
in various human gastrointestinal cancer cells and tissues
compared with their normal counterparts [22]. Actually,
ASK2 deﬁciency promotes chemically induced mouse skinInternational Journal of Cell Biology 3
tumorigenesis, through the reduction of apoptosis in DNA-
damaged epidermal keratinocytes during the initiation stage.
ASK2 has been shown to activate ASK1 by direct phosphory-
lation.
ASK1 also acts as a tumor suppressor in hepatocarcino-
genesis [17]. ASK1 is involved in death receptor-mediated
apoptosis through the JNK-mediated phosphorylation of
BimEL, a proapoptotic Bcl-2 family member, and the
DNA damage-induced upregulation of p21 through the p38
pathway.ASK1alsocontributestothedevelopmentofgastric
cancer [21]; the expression level of ASK1 increased in human
gastric cancer, and ASK1-deﬁcient mice had both fewer and
smaller tumors than wild-type mice. ASK1 upregulates the
expressionlevelofcyclinD1throughAP-1activation,leading
to cell proliferation. Moreover, cyclin D1 elevates ASK1
expression via the Rb-E2F pathway such that this positive
feedback loop facilitates the development of gastric cancer.
Thus, ASK1 functions as a tumor promoter and also as a
tumor suppressor, depending on the cell type and cellular
context, through the induction of various cellular responses,
such as apoptosis, inﬂammation, and cell proliferation. Most
recently, it has also been reported that frequent somatic
m u t a t i o n si nA S K 1i nm e t a s t a t i cm e l a n o m aw e r ei d e n t i ﬁ e d
by exome sequencing [23]. Several mutations aﬀect the
kinase activity of ASK1. The Ile780Phe substitution in the
kinase domain of ASK1 almost completely abolishes kinase
activity, whereas the Glu663Lys substitution adjacent to the
kinase domain reduces weakly, yet signiﬁcantly, the kinase
activity.
4. Neurodegenerative Diseases and ASK1
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by two pathological ﬁndings: amyloid-β (Aβ)
accumulation and neuroﬁbrillary tangles. Aβ is the major
componentofsenileplaquesandinducesneuronalcelldeath,
and it has been reported that Aβ impairs mitochondrial
redox activity and increases the generation of ROS, leading
to apoptotic neuronal death. Aβ also activates ASK1 through
the generation of ROS and induces JNK-mediated neuronal
cell death [13]. It has been observed that Aβ-induced neu-
ronal cell death decreases in ASK1-deﬁcient mice, indicating
that ROS-induced ASK1 activation by Aβ is an important
step in the pathogenesis of AD.
Recently, it has also been reported that ASK1-mediated
dopaminergic (DA) neuronal cell death is important for
Parkinson’s disease [14]. The peroxiredoxin 2 (Prx2) antiox-
idant enzyme inhibits DA toxin 6-hydroxydopamine-(6-
OHDA-) induced ASK1 activation by modulating the redox
status of Trx and inhibiting the dissociation of Trx from
ASK1. Prx2 confers remarkable protection against 6-OHDA-
induced DA neuronal loss via the suppression of the ASK1-
dependent activation of JNK and p38. In addition, the
oxidative stress-mediated activation of the ASK1-JNK path-
way is associated with brain ischemia in the hippocampus
[15]. Thus, ROS-induced ASK1 activation contributes to the
pathogenesis of neurodegenerative diseases.
5. Inﬂammation andASK1
ASK1 also responds to biological stresses, such as bacterial
and viral infection, and induces inﬂammation. Bacterial
components, such as LPS, are recognized by TLRs and
activate the downstream MAPK pathways. ASK1-deﬁcient
mice have been shown to be resistant to LPS-induced sepsis
shock [6]. The LPS-induced p38 activation and production
of inﬂammatory cytokines were reduced in splenocytes and
dendritic cells derived from ASK1-deﬁcient mice. Because
LPS-induced p38 activation and cytokine production were
suppressed by antioxidants, this implies that LPS-induced
ASK1 activation is mediated by ROS generation. These
results indicate that ASK1 is important for mammalian
innate immunity. In addition, recent research has shown
that the activation of the ASK1-p38 pathway through TLRs
in glial cells is important for chemokine production in
astrocytes and facilitates inﬂammation and neurotoxicity
in multiple sclerosis (MS) [16]. An ASK1 deﬁciency or
ASK1 inhibitor attenuated the sensitivity of experimental
autoimmune encephalomyelitis, an animal model of MS,
suggesting that ASK1 is a potential therapeutic target for the
treatment of MS.
6.CardiacDiseasesandASK1
ASK1 is closely linked to cardiac diseases, such as cardiac
hypertrophy, remodeling, and cardiac injury. It has been
reported that in the left ventricle, ASK1 is activated by
angiotensin-II-(Ang II-) induced ROS generation through
the Ang II type 1 (AT1) receptor, resulting in cardiac
hypertrophy and remodeling [18, 19]. Ang II-induced
cardiac hypertrophy and remodeling, including cardiac
hypertrophy-related mRNA upregulation, cardiomyocyte
apoptosis, and interstitial ﬁbrosis, were signiﬁcantly atten-
uated in ASK1-deﬁcient mice. ASK1 is also involved in
Ang II-induced cardiac injury, such as capillary endothelial
apoptosis, and a decrease in myocardial capillary density
[20]. Cardiac injury was prevented by an AT1 receptor
blocker through the inhibition of ROS generation and ASK1
activation in a mouse model of hypertensive decompensated
cardiac hypertrophy and heart failure. ASK1 contributes to
Ang II-induced cardiac diseases mediated by ROS genera-
tion.
7.DiabetesandASK1
Several studies have revealed that ASK1 is associated with
the pathogenesis of diabetes. ASK1 has been shown to
negatively regulate insulin receptor substrate-1 (IRS-1), a
key mediator in insulin signaling, through JNK-mediated
IRS-1 phosphorylation [24]. ASK1 is activated by TNF-α-
stimulated ROS generation and is an important factor that
causes insulin resistance. Hyperglycemia increases oxidative
stress in various tissues, and it has been reported that
the high glucose-induced activation of ASK1 contributes to
endothelial cell senescence, leading to diabetes-related vas-
cular aging mediated by oxidative stress [25]. These results
suggest that ROS-mediated ASK1 activation is involved in4 International Journal of Cell Biology
Table 1: ASK1-related diseases and pathologies.
Organ/tissue Related diseases Related pathologies References
Nervous system
Alzheimer’s disease Neuronal death [13]
Parkinson’s disease Neuronal death [14]
Brain ischemia Neuronal death [15]
Multiple sclerosis Inﬂammation [16]
Liver Hepatocarcinogenesis Apoptosis [17]
Heart Hypertrophy, remodeling
Cardiac injury




Stomach Gastric cancer Cell proliferation [21]
Skin Skin tumorigenesis Apoptosis, inﬂammation [22]
Immune system Infection Septic shock [6]
the pathogenesis of diabetes through the modulation of
insulin signaling or cellular senescence.
8. Conclusions
Redox balance is important for the control of cellular
responses, and the mode of cell reaction depends on the
level of oxidative stress. As described above, the ASK1
signaling pathway is closely linked to various human diseases
caused by oxidative stress and redox imbalance through the
regulation of various cellular responses, such as apoptosis,
inﬂammation, proliferation, and senescence. Recent studies
have shown that ASK1 is a therapeutic candidate for these
diseases (summarized in Table 1). ASK1 functions as an
initial sensor of ROS generation and plays a pivotal role
in signal transduction for the maintenance of homeostasis
against redox imbalance. The excessive activation and dys-
regulation of ASK1 result in a wide range of diseases. Further




ASK1: Apoptosis signal-regulating kinase 1
MAPK: Mitogen-activated protein kinase
JNK: c-Jun N-terminal kinase
TNF-α: Tumor necrosis factor-α
ROS: Reactive oxygen species
LPS: Lipopolysaccharide
Trx: Thioredoxin
TRAF: TNF-α receptor-associated factor
TLR: Toll-like receptor
Prx: Peroxiredoxin
Ang II: Angiotensin II.
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